Tag: Prescription Drugs
Mifepristone Efficacious for Adenomyosis
Total remission rates for dysmenorrhea significantly better for mifepristone versus placebo
Rituximab Not Noninferior to Ocrelizumab for Relapsing-Remitting MS
Cumulative hazard of relapses higher among patients treated with rituximab versus ocrelizumab
Alectinib Exposure Lower With Low-Fat Yogurt Intake
More patients taking alectinib with low-fat yogurt do not reach the exposure threshold of 435 ng/mL
Adolescent Residential Addiction Facilities Largely Do Not Provide Buprenorphine
Few offer other evidence-based treatments
New Threshold Could Inform Rabies Postexposure Prophylaxis Decisions
Authors say a risk threshold of 0.0004 would be appropriate for postexposure prophylaxis administration
Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia
Overall response rates >95 percent, regardless of high-risk features; 36-month PFS 88 and 92 percent for those with, without high-risk features
Outpatient Metformin Treatment Reduces Incidence of Long COVID
Beneficial effect of metformin consistent across subgroups
Valbenazine Yields Improvement in Chorea in Huntington Disease
Improvement seen in Unified Huntington's Disease Rating Scale Total Maximal Chorea with valbenazine versus placebo
ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer
No improvement seen in disease progression or death, and increase seen in serious adverse events with atezolizumab + cabozantinib
ASCO: Cilta-Cel Beneficial for Lenalidomide-Refractory Multiple Myeloma
Single cilta-cel infusion results in lower risk of disease progression or death compared with standard care
